Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

This study has been terminated.
(funding unavailable)
Sponsor:
Collaborators:
National Cancer Institute (NCI)
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
UNC Lineberger Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00577694
First received: December 19, 2007
Last updated: October 7, 2015
Last verified: October 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: August 2015
  Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)